Brightsurf Science News & Current Events

September 28, 2019
New blood test capable of detecting multiple types of cancer
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test led by Dana-Farber shows.

Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy
Liquid biopsy is likely to play an increasing role in identifying patients with colorectal cancer (CRC) who are likely to relapse after surgery, and has potential for optimising treatment for individual patients, according to new research presented at the ESMO Congress 2019.

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer (NSCLC), according to late breaking results of the FLAURA trial presented at the ESMO Congress 2019 in Barcelona, Spain.

One in two pts with metastatic melanoma alive after 5 years with combination immunotherapy
One in two patients with metastatic melanoma is alive with combination immunotherapy, according to late breaking results of the CheckMate 067 trial presented at the ESMO Congress 2019 in Barcelona, Spain.

Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates
A combination of 2 immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.

Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC
New data have shown that first-line treatment with a combination of two immunotherapy drugs improves overall survival in a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.

Taxi drivers face highest levels of black carbon compared to other professional drivers
Professional drivers working in congested cities are exposed to black carbon levels that are on average a third higher than would be experienced at a busy roadside, according to research presented at the European Respiratory Society International Congress.

Ovarian cancer: more women benefit from maintenance combined targeted therapy
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation.

New treatment improves survival in women newly diagnosed with advanced ovarian cancer
An international study shows that administering niraparib after chemotherapy reduces by nearly 40% the risk of relapse or death from this disease.

Additional heart artery stenting reduces risk of future heart attacks
Research has shown that patients who have had emergency heart attack treatment with heart artery stenting -- and have significant narrowings in their other untreated arteries -- can benefit from additional stenting to help prevent future heart attacks.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.